Literature DB >> 25658542

Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy.

S G Parisi1, L Sarmati2, S Andreis3, R Scaggiante3, M Cruciani4, R Ferretto5, V Manfrin6, M Basso3, M Andreoni2, C Mengoli3, G Palù3.   

Abstract

In a longitudinal study on 181 naïve patients who responded to therapy (mean follow-up 4 years), high baseline human immunodeficiency virus (HIV)-RNA values correlated with high levels of cellular HIV-DNA at all time points (p < 0.0001, p 0.045, p 0.0055, and p 0.0025, respectively) and negatively correlated with undetectable residual viremia (URV; <2.5 copies/mL) at T1, T2, and T3 (p 0.026, p 0.0149, and p 0.0002, respectively). Baseline high HIV-DNA levels predicted the persistence of high values (p 0.0001) and negatively correlated with URV (p 0.0254, p 0.0481, and p 0.0085). These results suggest that baseline viral load, cellular HIV-DNA, and URV were strongly correlated over long-term follow-up of antiretroviral therapy responders.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cellular HIV-DNA; HIV-RNA; naïve patients; primary infection; residual viremia

Mesh:

Substances:

Year:  2014        PMID: 25658542     DOI: 10.1016/j.cmi.2014.10.009

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  12 in total

1.  Platelets function as an acute viral reservoir during HIV-1 infection by harboring virus and T-cell complex formation.

Authors:  Sydney R Simpson; Meera V Singh; Stephen Dewhurst; Giovanni Schifitto; Sanjay B Maggirwar
Journal:  Blood Adv       Date:  2020-09-22

2.  Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.

Authors:  Saverio G Parisi; Samantha Andreis; Carlo Mengoli; Nicola Menegotto; Silvia Cavinato; Renzo Scaggiante; Massimo Andreoni; Giorgio Palù; Monica Basso; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2018-03-09       Impact factor: 3.402

3.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

Review 4.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

Review 5.  Factors Associated with the Size of HIV DNA Reservoir.

Authors:  Ni-Dan Wang; Tai-Sheng Li
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

6.  Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.

Authors:  Saverio Giuseppe Parisi; Monica Basso; Carlo Mengoli; Renzo Scaggiante; Samantha Andreis; Marzia Maria Franzetti; Anna Maria Cattelan; Daniela Zago; Mario Cruciani; Massimo Andreoni; Sara Piovesan; Giorgio Palù; Alfredo Alberti
Journal:  Ann Gastroenterol       Date:  2017-07-04

7.  Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.

Authors:  Nicola Gianotti; Alessandro Cozzi-Lepri; Andrea Antinori; Antonella Castagna; Andrea De Luca; Benedetto Maurizio Celesia; Massimo Galli; Cristina Mussini; Carmela Pinnetti; Vincenzo Spagnuolo; Antonella d'Arminio Monforte; Francesca Ceccherini-Silberstein; Massimo Andreoni
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

8.  The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.

Authors:  Thibault Mesplède; Jing Leng; Hanh Thi Pham; Jiaming Liang; Yudong Quan; Yingshan Han; Mark A Wainberg
Journal:  mBio       Date:  2017-04-04       Impact factor: 7.867

9.  Extremely low viral reservoir in treated chronically HIV-1-infected individuals.

Authors:  Cristina Gálvez; Victor Urrea; Judith Dalmau; Montse Jimenez; Bonaventura Clotet; Valérie Monceaux; Nicolas Huot; Lorna Leal; Victoria González-Soler; Maria González-Cao; Michaela Müller-Trutwin; Asier Sáez-Cirión; Felipe García; Julià Blanco; Javier Martinez-Picado; Maria Salgado
Journal:  EBioMedicine       Date:  2020-06-21       Impact factor: 8.143

10.  Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach.

Authors:  Carlo Mengoli; Monica Basso; Samantha Andreis; Renzo Scaggiante; Mario Cruciani; Roberto Ferretto; Sandro Panese; Vinicio Manfrin; Daniela Francisci; Elisabetta Schiaroli; Gaetano Maffongelli; Loredana Sarmati; Massimo Andreoni; Franco Baldelli; Giorgio Palu'; Saverio Giuseppe Parisi
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.